Persistent Tissue-Level Hypoperfusion (No-Reflow) Negates the Clinical Benefit of Successful Thrombectomy

Post time 2026-6-13 22:42:46

journal：Stroke

Authors：Samantha Rivet; Leonid Churilov; Nawaf Yassi; Timothy J. Kleinig; Vincent S. Thijs; Teddy Y. Wu; Helen M. Dewey; Patricia M. Desmond; Mark W. Parsons; Geoffrey A. Donnan; Stephen M. Davis; Peter J. Mitchell; Bruce C.V. Campbell; Felix C. Ng

Published date：2025-6-

DOI：10.1161/strokeaha.124.049574

PDF link：https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.124.049574

Article link：https://doi.org/10.1161/strokeaha.124.049574

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

[AHA] Persistent Tissue-Level Hypoperfusion (No-Reflow) Negates the Clinical Benefit of Successful Thrombectomy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AHA] Persistent Tissue-Level Hypoperfusion (No-Reflow) Negates the Clinical Benefit of Successful Thrombectomy Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AHA] Persistent Tissue-Level Hypoperfusion (No-Reflow) Negates the Clinical Benefit of Successful Thrombectomy